Escherichia coli-focused Research-grade Drug Discovery Service
With the persistent concern for bacterial infections and the escalating resistance to antibiotics, the need for innovative, research-driven solutions for Escherichia coli (E. coli) infections has never been more pressing. Creative Biolabs provides a high-potential drug discovery service that is dedicated to tackling E. coli infections.
E. coli Summary
-
E. coli is a Gram-negative bacterium, that can survive in both oxygen-rich and oxygen-poor environments, metabolizing a diverse range of substances. It uses mixed-acid fermentation in anaerobic conditions, producing a variety of acids and gases.
-
The harmless strains of E. coli can benefit the host by producing Vitamin K2, aiding digestion, and preventing the establishment of harmful bacteria within the intestine.
-
Shiga toxin-producing E. coli (STEC) is the most frequent source of E. coli infections. It can lead to severe stomach cramps, bloody diarrhea and vomiting.
-
Hemolytic uremic syndrome is a severe and sometimes fatal consequence that can result from certain types of E. coli infections. In addition, E. coli is the source of respiratory ailments, urinary tract infections, and other diseases.
-
E. coli strains are often used in scientific research, including genetic engineering and molecular biology, due to their simple genetics and ease of maintenance in the lab.
Fig.1 Mechanisms of probiotics towards host-E. coli interactions.1
Our Service Features
-
We offer a progressive, well-rounded approach towards the development of novel, effective therapies to counteract E. coli infections.
-
Our service employs state-of-the-art drug discovery technologies and techniques from the initial stages of research to the final stages of clinical trials.
-
Our extensive and integrated process includes target identification, target validation, hit identification, hit-to-lead optimization, and lead optimization.
-
Moreover, we pioneer in cheminformatics, bioinformatics, genomics, proteomics, and metabolomics, which enable us to accelerate the drug discovery pipeline and deliver high-potency drug candidates against E. coli infections.
Dedication to Personalized Solutions
We understand that E. coli strains can significantly vary, leading to a broad spectrum of infections and severity; thus, we offer personalized solutions. Our team works closely with you to understand the specific needs of your project, employing a tailored approach to produce the most viable drug candidates.
Quality Assurance
All tests are conducted with stringent adherence to international standards and regulations, ensuring the utmost quality assurance. We prioritize your research needs and maintain the highest degree of integrity throughout the discovery process. Rest assured, all stages of our research-grade drug discovery service are transparent, and regular progress reports will keep you comprehensive of the project's status.
Our team of resourceful scientists and researchers have spent years studying the biology of E. coli bacteria and their interaction with human hosts. Utilizing this knowledge and coupling it with the latest technologies such as high-throughput screening, computational chemistry, structure-based drug design, and medicinal chemistry, Creative Biolabs can design, and develop research-grade efficacious drug candidates that can fight E. coli infections efficiently. Please contact us to learn more.
Reference:
-
Hwang, Su-bin, et al. "Role of recent therapeutic applications and the infection strategies of Shiga toxin-producing Escherichia coli." Frontiers in cellular and infection microbiology 11 (2021): 614963.
For Research Use Only. We do not provide direct services or products for patients.
Related Services:
